Stock Events

Stock Events

Benevolent AI 

€0.09
3
-€0.03-27.83% Wednesday 08:59

Statistics

Day High
0.09
Day Low
0.09
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
2.72
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Oct 19
€0.01
May 19
€0.02
Oct 18
€0.01
May 18
€0.02
Oct 17
€0.04
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

13MarExpected
Q2 2022
Q4 2023
Q2 2024
Q4 2024
-1.24
-0.81
-0.37
0.06
Expected EPS
-0.0250549689872
Actual EPS
N/A

Financials

-863.69%Profit Margin
Unprofitable
2021
2022
2023
7.33MRevenue
-63.32MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2XA.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, a large pharmaceutical company, competes in drug discovery using AI, similar to Benevolent AI's approach.
Pfizer
PFE
Mkt Cap140.15B
Pfizer uses advanced AI in drug discovery and development, directly competing with Benevolent AI's core business.
Novartis
NVS
Mkt Cap237.61B
Novartis invests heavily in digital technologies for healthcare, including AI, positioning them as a competitor in the AI-driven pharma sector.
Merck
MRK
Mkt Cap214.76B
Merck is engaged in AI for drug discovery, competing in the same space as Benevolent AI.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly utilizes AI in drug development, making them a competitor in the pharmaceutical AI applications arena.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals uses AI for genomic and drug discovery research, competing with Benevolent AI.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals incorporates AI in drug discovery, particularly in treating cystic fibrosis, competing with Benevolent AI.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb uses AI to enhance drug discovery and development processes, aligning as a competitor.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's focus on biotechnology and AI for therapeutic developments places them as a competitor.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie integrates AI in its R&D, particularly in areas like oncology and immunology, competing with Benevolent AI's technology-driven approach.

About

Odyssey Acquisition S.A. intends to complete a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination in healthcare, technology, media, and telecom sectors. The company was incorporated in 2021 and is based in Luxembourg, Luxembourg.
Show more...
CEO
Mr. Simon J. Breakwell
Country
LU
ISIN
LU2355630455
WKN
000A3CTVP

Listings

0 Comments

Share your thoughts

FAQ

What is Benevolent AI stock price today?▼
The current price of 2XA.F is €0.09 EUR — it has decreased by -27.83% in the past 24 hours. Watch Benevolent AI stock price performance more closely on the chart.
What is Benevolent AI stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Benevolent AI stocks are traded under the ticker 2XA.F.
What is Benevolent AI revenue for the last year?▼
Benevolent AI revenue for the last year amounts to 7.33M EUR.
What is Benevolent AI net income for the last year?▼
2XA.F net income for the last year is -63.32M EUR.
Does Benevolent AI pay dividends?▼
Yes, 2XA.F dividends are paid semi-annual. The last dividend per share was 0.01 EUR. As of today, Dividend Yield (FWD)% is 0%.
In which sector is Benevolent AI located?▼
Benevolent AI operates in the Financials sector.
When did Benevolent AI complete a stock split?▼
Benevolent AI has not had any recent stock splits.
Where is Benevolent AI headquartered?▼
Benevolent AI is headquartered in Basingstoke, LU.